Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
1 month ago
P1 data • Journal • Combination therapy • Metastases
|
PD-1 (Programmed cell death 1)
|
albumin-bound paclitaxel • Shan Ke Yu (socazolimab)
Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized osteosarcoma patients.